Abstracto

Alefacept

Alan Menter and Jennifer C Cather

Plaque psoriasis is a chronic inflammatory and hyperproliferative skin disease characterized by an increase in memory effector T-cells within psoriatic lesions. An increased understanding of the pathophysiology of psoriasis coupled with biotechnologic advances has led to the development of more specific targeted therapies. These therapies have the potential to provide a specific therapeutic intervention while avoiding potential adverse events associated with traditional systemic agents. Alefacept is a novel biologic agent that selectively reduces memory T-cells whilst leaving naive T-cell populations intact. This article reviews the clinical profile of alefacept in the treatment of psoriasis and other emerging indications. Emphasis is on the results of recently published data designed to clarify the optimal use of this promising new therapeutic option.